Safety of antiandrogen therapy for treating prostate cancer.

@article{Ricci2014SafetyOA,
  title={Safety of antiandrogen therapy for treating prostate cancer.},
  author={Francesco Ricci and Giulia Buzzatti and Alessandra Rubagotti and Francesco M. Boccardo},
  journal={Expert opinion on drug safety},
  year={2014},
  volume={13 11},
  pages={
          1483-99
        }
}
INTRODUCTION Antiandrogens are a treatment option in patients with prostate cancer, given either in combination with androgen deprivation or, in selected cases, as monotherapy. New-generation antiandrogens have been recently introduced in clinical practice (enzalutamide) or are under evaluation in clinical trials (ARN-509). AREAS COVERED This review elucidates the safety profile of antiandrogens, in particular focusing on the tolerability profile of each drug either when employed in… CONTINUE READING
BETA
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 101 REFERENCES

Increased survival with enzalutamide in prostate cancer after chemotherapy.

  • The New England journal of medicine
  • 2012
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Enzalutamide in metastatic prostate cancer before chemotherapy.

  • The New England journal of medicine
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Abiraterone in metastatic prostate cancer without previous chemotherapy.

  • The New England journal of medicine
  • 2013
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…